J Liver Cancer.  2024 Sep;24(2):129-130. 10.17998/jlc.2024.08.26.

The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases

• Kim BK

• KMID: 2559460
• DOI: http://doi.org/10.17998/jlc.2024.08.26

Reference

References

1. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28:583–705.

2. Goh MJ, Sinn DH, Kim JM, Lee MW, Hyun DH, Yu JI, et al. Clinical practice guideline and real-life practice in hepatocellular carcinoma: a Korean perspective. Clin Mol Hepatol. 2023; 29:197–205.

3. Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer. 2021; 10:107–114.

4. Lee HS. Management of patients with hepatocellular carcinoma and extrahepatic metastasis. Dig Dis. 2011; 29:333–338.

5. Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, NeumannHaefelin C, et al. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol. 2017; 17:98.

6. Song BG, Goh MJ, Kang W, Sinn DH, Gwak GY, Paik YH, et al. Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy. J Liver Cancer. 2024; Jun. 3. . doi: 10.17998/jlc.2024.05.26 [Epub ahead of print].

7. Luo Y, Huang X, Chen J, Zhang S. Evaluation of the clinical efficacy of intensity-modulated radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with extrahepatic oligometastasis and prognostic factors for patient survival. Int J Gen Med. 2023; 16:1271–1278.

8. Kim TH, Nam TK, Yoon SM, Kim TH, Choi YM, Seong J. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04). Cancers (Basel). 2022; 14:5848.

9. Huang ZM, Han X, Wang J, Gu L, Tang L, Wu SY, et al. A prospective, single-arm, phase 2 study of modified transarterial chemoembolization using low-dose chemotherapy with blank microspheres plus lowdose lenvatinib and microwave ablation in patients with large (≥7 cm) unresectable hepatocellular carcinoma: the TALEM trial. Liver Cancer. 2024; 13:438–450.

10. Zheng Y, Xiang Y, Shi H, Lin Z, Cheng S, Zhu J. Transarterial chemoembolization combined with atezolizumab plus bevacizumab versus transarterial chemoembolization alone in intermediate-stage hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma. 2024; 11:1079–1093.